Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | CES2 | O00748 | 1/20 | 0.58 |
| ▸ | CES1 | P23141 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5162864 | 0.88 | ALDH1A1 (0.59) | ALDH1A1KDM4ECES2CES1L3MBTL1 | |
| SCHEMBL3816367 | 0.86 | KMT2A (0.59) | ALDH1A1KDM4ECES2CES1L3MBTL1 | |
| SCHEMBL1515056 | 0.84 | — | — | |
| SCHEMBL28251547 | 0.82 | ALDH1A1 (0.64) | ALDH1A1KDM4ECES2CES1L3MBTL1 | |
| SCHEMBL947176 | 0.82 | — | — | |
| SCHEMBL1930639 | 0.82 | — | — | |
| SCHEMBL3813782 | 0.81 | CTNNB1 (0.58) | ALDH1A1KDM4ECES2CES1L3MBTL1 | |
| SCHEMBL2644284 | 0.81 | ALDH1A1 (0.47) | ALDH1A1KDM4ECES2CES1L3MBTL1 | |
| SCHEMBL13130702 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4ECES2CES1L3MBTL1 | |
| SCHEMBL13130697 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4ECES2CES1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420684-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome, Huntington's Disease; hypotensive agents; sleeping/eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 4-Cyclopropylimino-5-(3,4-dihydro-2H-pyran-2-yl)-1-(3-imidazol-1-yl-propyl)-imidazolidin-2-one | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| US-8263548-B2 | Metal-binding compounds and uses therefor | DMI BIOSCIENCES, INC. | 2012-09-11 | — | — | US | disclosed |
| US-8188215-B2 | Metal-binding compounds and uses therefor | AMPIO PHARMACEUTICALS, INC. | 2012-05-29 | — | — | US | disclosed |
| US-20110263817-A1 | METAL-BINDING COMPOUNDS AND USES THEREFOR | AMPIO PHARMACEUTICALS, INC. | 2011-10-27 | — | — | US | disclosed |
| US-8017728-B2 | Metal-binding compounds and uses therefor | AMPIO PHARMACEUTICALS, INC. | 2011-09-13 | — | — | US | disclosed |
| US-20110212902-A1 | METAL-BINDING COMPOUNDS AND USES THEREFOR | AMPIO PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-20110212903-A1 | METAL-BINDING COMPOUNDS AND USES THEREFOR | AMPIO PHARMACEUTICALS, INC. | 2011-09-01 | — | — | US | disclosed |
| US-7973008-B2 | Metal-binding compounds and uses therefor | DMI BIOSCIENCES, INC. | 2011-07-05 | — | — | US | disclosed |
| EP-2327713-A1 | Metal-binding compounds and uses therefor | DMI Biosciences, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100249016-A1 | METAL-BINDING COMPOUNDS AND USES THEREFOR | DMI BIOSCIENCES, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2003043518-A2 | METHODS AND PRODUCTS FOR ORAL CARE | DMI BIOSCIENCES, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-20030060408-A1 | Metal-binding compounds and uses therefor | AMPIO PHARMACEUTICALS, INC. | 2003-03-27 | — | — | US | disclosed |
| US-20030055003-A1 | Use of copper chelators to inhibit the inactivation of protein C | AMPIO PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003007686-A2 | USE OF COPPER CHELATORS TO INHIBIT THE INACTIVATION OF PROTEIN C | DMI BIOSCIENCES, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| CN-1390231-A | Metal-binding compound and use thereof | DMI BIOLOG SCIENCE CO (US) | 2003-01-08 | — | — | CN | disclosed |
| WO-2002064620-A2 | METAL-BINDING COMPOUNDS AND USES THEREFOR | DMI BIOSCIENCES, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
| EP-1220870-A1 | METAL-BINDING COMPOUNDS AND USES THEREFOR | DMI Biosciences, Inc. (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-1165738-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001025265-A1 | METAL-BINDING COMPOUNDS AND USES THEREFOR | DMI BIOSCIENCES, INC. (US) | 2001-04-12 | — | — | WO | disclosed |
| WO-2000060044-A1 | COMPOSITION AND METHOD FOR BLEACHING A SUBSTRATE | UNILEVER PLC (GB) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055003-A1 | Use of copper chelators to inhibit the inactivation of protein C | APC, PROC, CDC20 | ALDH1A1 2830/4885KDM4E 3601/4885CES2 3588/4885 |
| US-20030060408-A1 | Metal-binding compounds and uses therefor | SLC39A11, ROS1, NOX4 | ALDH1A1 538/4885KDM4E 3547/4885CES2 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.